2017 共识声明:抗肿瘤坏死因子治疗炎症性肠病治疗药物监测

2017-10-13 国外消化科相关专家小组(统称) Aliment Pharmacol Ther. 2017 Oct 13.

炎症性肠病(IBD)接受抗肿瘤坏死因子(TNF)药物治疗进行治疗药物监测(TDM)可以协助优化疾病结局。本文的主要目的是确定TDM指导抗肿瘤坏死因子药物治疗IBD的循证共识声明。由25位来自澳大利亚和国际专家共同组成专家小组共提出了24条共识意见。

中文标题:

2017 共识声明:抗肿瘤坏死因子治疗炎症性肠病治疗药物监测

英文标题:

consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.

发布日期:

2017-10-13

简要介绍:

炎症性肠病(IBD)接受抗肿瘤坏死因子(TNF)药物治疗进行治疗药物监测(TDM)可以协助优化疾病结局。本文的主要目的是确定TDM指导抗肿瘤坏死因子药物治疗IBD的循证共识声明。由25位来自澳大利亚和国际专家共同组成专家小组共提出了24条共识意见。

拓展指南:炎症性肠病相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2017 共识声明:抗肿瘤坏死因子治疗炎症性肠病治疗药物监测)] GetToolGuiderByIdResponse(projectId=1, id=9ef291c001509341, title=2017 共识声明:抗肿瘤坏死因子治疗炎症性肠病治疗药物监测, enTitle=consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases., guiderFrom=Aliment Pharmacol Ther. 2017 Oct 13., authorId=null, author=, summary=炎症性肠病(IBD)接受抗肿瘤坏死因子(TNF)药物治疗进行治疗药物监测(TDM)可以协助优化疾病结局。本文的主要目的是确定TDM指导抗肿瘤坏死因子药物治疗IBD的循证共识声明。由25位来自澳大利亚和国际专家共同组成专家小组共提出了24条共识意见。, cover=, journalId=null, articlesId=null, associationId=950, associationName=国外消化科相关专家小组(统称), associationIntro=null, copyright=0, guiderPublishedTime=Fri Oct 13 00:00:00 CST 2017, originalUrl=, linkOutUrl=, content=<P>炎症性肠病(IBD)接受抗肿瘤坏死因子(TNF)药物治疗进行治疗药物监测(TDM)可以协助优化疾病结局。本文的主要目的是确定TDM指导抗肿瘤坏死因子药物治疗IBD的循证共识声明。由25位来自澳大利亚和国际专家共同组成专家小组共提出了24条共识意见。</P>拓展指南:<strong>与<font color=red>炎症性肠病</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=2dc9f1c0015030f6" title="抗肿瘤坏死因子α单克隆抗体治疗炎症性肠病专家共识(2017)" target=_blank>抗肿瘤坏死因子α单克隆抗体治疗炎症性肠病专家共识(2017)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=6c0a31c001a8e4da" title="建立全国通用的炎症性肠病诊治过程的关键性质量控制指标的共识意见" target=_blank>建立全国通用的炎症性肠病诊治过程的关键性质量控制指标的共识意见</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=5ca8f1c001ae419c" title="炎症性肠病合并机会性感染专家共识意见" target=_blank>炎症性肠病合并机会性感染专家共识意见</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=a66e71c001a561cf" title="2013 NICE诊断指南:炎症性肠病粪便钙卫蛋白诊断测试(DG.11)" target=_blank>2013 NICE诊断指南:炎症性肠病粪便钙卫蛋白诊断测试(DG.11)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=4f5311c001a3e08b" title="【专题】世界炎症性肠病日,精选指南伴你健康行" target=_blank>【专题】世界炎症性肠病日,精选指南伴你健康行</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E7%82%8E%E7%97%87%E6%80%A7%E8%82%A0%E7%97%85" target=_blank>有关炎症性肠病更多指南</a></ul>, tagList=[TagDto(tagId=9498, tagName=抗肿瘤坏死因子), TagDto(tagId=1125, tagName=炎症性肠病), TagDto(tagId=58401, tagName=治疗药物监测)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=4, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4779, appHits=122, showAppHits=0, pcHits=3383, showPcHits=1784, likes=180, shares=1, comments=4, approvalStatus=1, publishedTime=Thu Oct 19 13:13:13 CST 2017, publishedTimeString=2017-10-13, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Thu Oct 19 13:13:13 CST 2017, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 04:35:26 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2017 共识声明:抗肿瘤坏死因子治疗炎症性肠病治疗药物监测)])
2017 共识声明:抗肿瘤坏死因子治疗炎症性肠病治疗药物监测
下载请点击:
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=361067, encodeId=e8f136106e3a, content=正在学习。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98062550206, createdName=天天作西, createdTime=Wed Feb 20 05:42:28 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254751, encodeId=f9b6254e5185, content=学习学习.了解了解, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sat Oct 21 06:34:46 CST 2017, time=2017-10-21, status=1, ipAttribution=)]
    2019-02-20 天天作西

    正在学习。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=361067, encodeId=e8f136106e3a, content=正在学习。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98062550206, createdName=天天作西, createdTime=Wed Feb 20 05:42:28 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254751, encodeId=f9b6254e5185, content=学习学习.了解了解, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sat Oct 21 06:34:46 CST 2017, time=2017-10-21, status=1, ipAttribution=)]
    2017-10-21 1dd8c52fm63(暂无匿称)

    学习学习.了解了解

    0